IDH1 R132 in MDS — ivosidenib monotherapy active (DiNardo et al. JCO 2021 — ORR 75% MDS,...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-IDH1-R132H-MDS-LR |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MDS-LR |
| Sources | SRC-CIVIC SRC-ESMO-MDS-2021 |
Actionability Facts
| Biomarker | BIO-IDH-MUTATION |
|---|---|
| Variant | IDH1 R132H |
| Disease | DIS-MDS-LR |
| ESCAT tier | IIA |
| Recommended combinations | ivosidenib (off-label MDS), ivosidenib + azacitidine (trial) |
| Evidence summary | IDH1 R132 in MDS — ivosidenib monotherapy active (DiNardo et al. JCO 2021 — ORR 75% MDS, CR 38%). Ivosidenib + azacitidine combos in trial. Off-label NCCN-supported. |
Notes
ESCAT IIA.
Used By
No reverse references found in the YAML corpus.